Trips Agreement And Its Impact On Pharmaceuticals

Created in the early 1990s by industry associations and regulators in the US, EU and Japan (home to most of the world`s multinational pharmaceutical companies), ICH is about reducing drug development costs, minimising regulatory requirements and speeding up marketing authorisation processes to promote market access [48].